68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Inclusion Criteria: * Known diagnosis of neuroendocrine tumor or suspected SSTR positive tumors by 111In-Octreotide scan, 18FDG-PET, or MRI of the abdomen where clinically indicated * At least 18 years of age * Able to provide informed consent * Karnofsky performance score greater than 50 * Females of childbearing potential must have a negative pregnancy test at screening/baseline Exclusion Criteria: * Serum creatinine \> 2.0 mg/dL * Hepatic enzyme levels more than 3 times upper limit of normal * Known severe allergy or hypersensitivity to IV radiographic contrast * Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments * Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT, and MRI that will result * Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.) * Inability to complete the needed investigational standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Recognized concurrent active infection * Previous systemic or radiation treatment for another cancer of any type within the last 2 years * Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance